Skip to main content

The CTD² Network and Cancer Systems Biology Consortium organized a virtual symposium series titled “Multidisciplinary Approaches to Understand Cancer Treatment Resistance”. Please join us on 11/16, 11/17, 12/2, 12/16, and 12/17. Click here to view the registration website.

Publications

644 Publications Available
BMC Cancer

Researchers demonstrate with a selection of clinical phenotypes and treatment variables, a statistically useful and biologically meaningful gene signature of Papillary thyroid carcinoma prognosis, which may be developed as a biomarker to help prevent overdiagnosis.

Elife

Investigators introduce a comprehensive algorithm that incorporates chromatin, position, and sequence features to accurately predict highly effective single guide RNAs (sgRNAs) for targeting nuclease-dead Cas9-mediated transcriptional repression (CRISPRi) and activation (CRISPRa).

Cancer Discovery

DNA methylation enzyme EZH2 may be a potential epigenetic target for lung cancer treatment.

Journal of Clinical Investigation

ZEB1-induced EMT and associated molecular changes in ESRP1 and CD44 contribute to early pathogenesis and metastatic potential in established lung cancer. TGF-β, VDR signaling and CD44 splicing pathways associated with ZEB1 are potential EMT chemoprevention and therapeutic targets in NSCLC.

The Journal of Physiology
ACS Chemical Biology

Researchers present an unrecognized role of sialic acid metabolism and protein sialylation in regulating the expression of genes that maintain breast cancer pathogenicity.

Cell

Researchers discuss combined targeting of the EGFR effector AKT and the glutathione antioxidant pathway mimicked Nrf2 ablation to potently inhibit pancreatic cancer ex vivo and in vivo, representing a promising synthetic lethal strategy for treating the disease.

Genome Medicine

Researchers at UCSF have identified Pannexin 3 as a candidate gene that links body mass index (BMI) and carcinogenesis.